Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Cystic Fibrosis Foundation
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference26 articles.
1. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
3. US Food and Drug Administration . FDA approves new breakthrough therapy for cystic fibrosis. https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis. Date last updated: 21 October 2019.
4. European Medicines Agency . Kaftrio. https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio. Date last updated: 26 July 2023.
5. European Commission . Kaftrio. https://ec.europa.eu/health/documents/community-register/html/h1468.htm. Date last updated: 4 September 2023.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献